Compounds with Combined Cancer Drug Scaffolds Inhibit Cancer Cell Proliferation at Nanomolar Concentrations

Back to all technologies
Download as PDF
Purdue University researchers have developed compounds that are anti-proliferative against multiple cancer cell types. Cancer results from genetic alterations that impose uncontrolled proliferation of cells. Therefore, developing molecules to debilitate cellular proliferation would prove an effective treatment for cancers. Purdue researchers optimized a synthetic method to quickly synthesize a library of compounds containing combined cancer drug scaffolds via a multi-component Povarov reaction. The researchers investigated the anti-proliferative effects of the compounds by a primary screen in the MDA-MB-231 triple-negative breast cancer cell line. Analogs of the most potent compounds were further tested against the NCI-60 cancer cell panel and exhibited anti-proliferative effects on melanoma, leukemia, breast, lung, and renal cancer cell lines with GI50 values at sub micromolar concentrations. These molecules are also promising because they have a high fraction of sp3 carbons increasing their drug like characteristics. The compounds' potency toward multiple cancer cell lines and drug like properties make them promising candidates for future therapeutic development.

-Combined Anti-Cancer Scaffold
-Easily Synthesized Compounds
-Increased Drug-Like Characteristics

-Cancer Therapies
-Cancer Relapse Therapies

Related Publication:
HSD1787, a Tetrahydro-3H-Pyrazolo[4,3-f]Quinoline Compound Synthesized via Povarov Reaction, Potently Inhibits Proliferation of Cancer Cell Lines at Nanomolar Concentrations
ACS Omega 2020, 5, 37, 23799-23807
DOI: 10.1021/acsomega.0c03001
Jul 1, 2021

Jul 2, 2020
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486